Literature DB >> 20190143

IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages.

Xiyuan Bai1, Soo-Hyun Kim, Tania Azam, Mischa T McGibney, Hua Huang, Charles A Dinarello, Edward D Chan.   

Abstract

Macrophages provide a first line of defense against Mycobacterium tuberculosis. However, in instances where macrophage activation for killing is suboptimal, M. tuberculosis is capable of surviving intracellularly. IL-32 is a recently described cytokine induced by M. tuberculosis in a variety of cell types including human monocytes and macrophages. In this study, we investigated the biological significance of IL-32 in an in vitro model of M. tuberculosis infection in differentiated THP-1 human macrophages in which IL-32 expression was silenced using stable expression of short hairpin RNA (shRNA). Inhibition of endogenous IL-32 production in THP-1 cells that express one of three distinct shRNA-IL-32 constructs significantly decreased M. tuberculosis induction of TNF-alpha by approximately 60%, IL-1beta by 30-60%, and IL-8 by 40-50% and concomitantly increased the number of cell-associated M. tuberculosis bacteria compared with THP-1 cells stably expressing a scrambled shRNA. In THP-1 cells infected with M. tuberculosis and stimulated with rIL-32, a greater level of apoptosis was observed compared with that with M. tuberculosis infection alone. Obversely, there was significant abrogation of apoptosis induced by M. tuberculosis and a concomitant decrease in caspase-3 activation in cells depleted of endogenous IL-32. rIL-32gamma significantly reduced the number of viable intracellular M. tuberculosis bacteria, which was modestly but significantly abrogated with a caspase-3 inhibitor. We conclude that IL-32 plays a host defense role against M. tuberculosis in differentiated THP-1 human macrophages.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190143     DOI: 10.4049/jimmunol.0901913

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis.

Authors:  Jida Choi; Suyoung Bae; Jaewoo Hong; Soyoon Ryoo; Hyunjhung Jhun; Kwangwon Hong; Doyoung Yoon; Siyoung Lee; Erk Her; Wonhyuk Choi; Jeonghwan Kim; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Neuroinflammatory and Amyloidogenic Activities of IL-32β in Alzheimer's Disease.

Authors:  Hyung-Mun Yun; Jin A Kim; Chul Ju Hwang; Peng Jin; Myung Ki Baek; Jin Moo Lee; Ji Eun Hong; Sang Min Lee; Sang Bae Han; Ki Wan Oh; Dong Young Choi; Do Young Yoon; Jin Tae Hong
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

3.  Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.

Authors:  Laurent Gorvel; Daniel Korenfeld; Thomas Tung; Eynav Klechevsky
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

4.  NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy.

Authors:  Mirjam Schenk; Stephan R Krutzik; Peter A Sieling; Delphine J Lee; Rosane M B Teles; Maria Teresa Ochoa; Evangelia Komisopoulou; Euzenir N Sarno; Thomas H Rea; Thomas G Graeber; Soohyun Kim; Genhong Cheng; Robert L Modlin
Journal:  Nat Med       Date:  2012-03-25       Impact factor: 53.440

5.  Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.

Authors:  Xiyuan Bai; Shaobin Shang; Marcela Henao-Tamayo; Randall J Basaraba; Alida R Ovrutsky; Jennifer L Matsuda; Katsuyuki Takeda; Mallory M Chan; Azzeddine Dakhama; William H Kinney; Jessica Trostel; An Bai; Jennifer R Honda; Rosane Achcar; John Hartney; Leo A B Joosten; Soo-Hyun Kim; Ian Orme; Charles A Dinarello; Diane J Ordway; Edward D Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-27       Impact factor: 11.205

6.  IL-32 is a molecular marker of a host defense network in human tuberculosis.

Authors:  Dennis Montoya; Megan S Inkeles; Phillip T Liu; Susan Realegeno; Rosane M B Teles; Poorva Vaidya; Marcos A Munoz; Mirjam Schenk; William R Swindell; Rene Chun; Kathryn Zavala; Martin Hewison; John S Adams; Steve Horvath; Matteo Pellegrini; Barry R Bloom; Robert L Modlin
Journal:  Sci Transl Med       Date:  2014-08-20       Impact factor: 17.956

7.  Transcriptional Response of Respiratory Epithelium to Nontuberculous Mycobacteria.

Authors:  Masashi Matsuyama; Andrew J Martins; Shamira Shallom; Olena Kamenyeva; Anuj Kashyap; Elizabeth P Sampaio; Juraj Kabat; Kenneth N Olivier; Adrian M Zelazny; John S Tsang; Steven M Holland
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

8.  IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease.

Authors:  Xiyuan Bai; Alida R Ovrutsky; Marinka Kartalija; Kathryn Chmura; Amanda Kamali; Jennifer R Honda; Rebecca E Oberley-Deegan; Charles A Dinarello; James D Crapo; Ling-Yi Chang; Edward D Chan
Journal:  Int Immunol       Date:  2011-10-27       Impact factor: 4.823

9.  Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Authors:  Bas Heinhuis; Marije I Koenders; Wim B van den Berg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

10.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.